Atrogi receives regulatory approval from German health authority BfArM to initiate phase 1 study of ATR-258 in type 2 diabetes
First small molecule drug targeting adrenergic receptors to promote glucose uptake in skeletal muscle for the treatment of type 2 diabetes Stockholm, Sweden, March 22, 2022. Atrogi, an early-stage Swedish pharma company developing a novel solution for the treatment of type 2 diabetes, today announces that it has received approval from the German authority BfArM to initiate a phase 1 study with their small molecule drug candidate ATR-258 in healthy volunteers and type 2 diabetics. The trial is expected to be completed by year end 2022 with the final report in Q1/2,2023.ATR-258 is based on